Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age

Modern Pathology

Volumn 20, Issue 12, 2007, Pages 1307-1315

  Skaland, Ivar ^a,b   Janssen, Emiel A M ^a,b   Gudlaugsson, Einar ^a,b   Klos, Jan ^a   Kjellevold, Kjell H ^a   Søiland, Håvard ^a,b   Baak, Jan P A ^a,b,c  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Breast cancer; Mitotic activity index; Phosphohistone H3

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; HISTONE H3; METHOTREXATE;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; DIGITAL IMAGING; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; METASTASIS; MITOSIS RATE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; TUMOR VOLUME;

BREAST NEOPLASMS; FEMALE; HISTONES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPH NODES; MIDDLE AGED; MITOTIC INDEX; PROGNOSIS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 36249024271     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800972     Document Type: Article

References (41)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
2. Baak JP, Colpaert CG, van Diest PJ, et al. Multivariate prognostic evaluation of the activity index and fibrotic focus in node-negative invasive breast cancers. Eur J Cancer 2005;41:2093-2101.
3. Baak JP, van Diest PJ, Voorhorst FJ, et al. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph nodenegative breast cancer patients younger than 55 years. J Clin Oncol 2005;23:5993-6001.
4. Baak JPA, van Dop H, Kurver PHJ, et al. The value of morphometry to classic prognostic variables in breast cancer. Cancer 1985;56:374-382.
5. Bergers E, Baak JP, van Diest PJ, et al. Prognostic implications of different cell cycle analysis models of flow cytometric DNA histograms of 1301 breast cancer patients: results from the Multicenter Morphometric Mammary Carcinoma Project. Int J Cancer 1997;74:260-269.
6. Groenendijk RP, Bult P, Noppen CM, et al. Mitotic activity index in interval breast cancers. Eur J Surg Oncol 2003;29:29-31.
7. Manders P, Bult P, Sweep CG, et al. The prognostic value of the mitotic activity index in patients with primary breast cancer who were not treated with adjuvant systemic therapy. Breast Cancer Res Treat 2003;77:77-84.
8. Meyer JS, Alvarez C, Milikowski C, et al. Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index. Mod Pathol 2005;18:1067-1078.
9. Sigurdsson H, Baldetorp B, Borg A, et al. Indicators of prognosis in node-negative breast cancer. N Engl J Med 1990;322:1045-1053.
10. Silvestrini R, Daidone MG, Di Fronzo G, et al. Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Res Treat 1986;7:161-169.
11. Thor AD, Liu S, Moore II DH, et al. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol 1999;17:470-477.
12. Tosi P, Luzi P, Sforza V, et al. Correlation between morphometrical parameters and disease-free survival in ductal breast cancer treated only by surgery. Appl Pathol 1986;4:33-42.
13. Uyterlinde AM, Baak JP, Schipper NW, et al. Prognostic value of morphometric and DNA flow-cytometry features of invasive breast cancers detected by population screening: comparison with control group of hospital patients. Int J Cancer 1991;48:173-181.
14. van der Linden JC, Baak JP, Lindeman J, et al. Prospective evaluation of prognostic value of morphometry in patients with primary breast cancer. J Clin Pathol 1987;40:302-306.
15. van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 2004;57:675-681.
16. Volpi A, Bacci F, Paradiso A, et al. Prognostic relevance of histological grade and its components in node-negative breast cancer patients. Mod Pathol 2004;17:1038-1044.
17. Baak JP, van Diest PJ, Voorhorst FJ, et al. The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent. Eur J Cancer 2007;43:527-535.
18. Fleege JC, Diest PJ, Baak JPA. Reliability of quantitative pathological assessments: counting mitoses. In: Baak JPA (ed). Manual of Quantitative Pathology in Cancer Diagnosis and Prognosis. Springer: New York, 1991, pp 169-172.
19. Sims AH, Ong KR, Howell A, et al. High-throughput genomic technology in research and clinical management of exploiting the potential of gene expression profiling: is it ready for the clinic? Breast Cancer Res 2006;8:214.
20. Dai H, van't Veer L, Lamb J, et al. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 2005;65:4059-4066.
21. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-272.
22. Amadori D, Nanni O, Marangolo M, et al. Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study. J Clin Oncol 2000;18:3125-3134.
23. Andre F, Khalil A, Slimane K, et al. Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer. J Clin Oncol 2005;23:2996-3000.
24. Fiets WE, Bellot FE, Struikmans H, et al. Prognostic value of mitotic counts in axillary node negative breast cancer patients with predominantly well-differentiated tumours. Eur J Surg Oncol 2005;31:128-133.
25. Westenend PJ, Meurs CJ, Damhuis RA. Tumour size and vascular invasion predict distant metastasis in stage I breast cancer. Grade distinguishes early and late metastasis. J Clin Pathol 2005;58:196-201.
26. Jannink I, Risberg B, Van Diest PJ, et al. Heterogeneity of mitotic activity in breast cancer. Histopathology 1996;29:421-428.
27. Bergers E, Jannink I, van Diest PI, et al. The influence of fixation delay on mitotic activity and flow cytometric cell cycle variables. Hum Pathol 1997;28:95-100.
28. van Diest PJ, Baak JP, Matze-Cok P, et al. Reproducibility of mitosis counting in 2469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 1992;23:603-607.
29. Brenner RM, Slayden OD, Rodgers WH, et al. Immunohistochemical assessment of mitotic activity with an antibody to phosphorylated histone PPH3 in the macaque and human endometrium. Hum Reprod 2003;18:1185-1193.
30. Hendzel MJ, Wei Y, Mancini MA, et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 phase and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 1997;106:348-360.
31. Juan G, Traganos F, James WM, et al. Histone PPH3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis. Cytometry 1998;32:71-77.
32. Juan G, Traganos F, Darzynkiewicz Z. Histone PPH3 phosphorylation in human monocytes and during HL-60 cell differentiation. Exp Cell Res 1999;246:212-220.
33. Bossard C, Jarry A, Colombeix C, et al. PPH3-based a phosphohistone PPH3 labelling for histoprognostic grading of breast adenocarcinomas and computer-assisted determination of mitotic index. J Clin Pathol 2006;59:706-710.
34. Tavassoli FA, Devilee P (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press: Lyon, 2003, pp 9-112.
35. Eppenberger-Castori S, Moore Jr DH, Thor AD, et al. Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol 2002;34:1318-1330.
36. Sloane JP, Amendoeira I, Apostolikas N, et al. Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. European Commission Working Group on Breast Screening Pathology. Virchows Arch 1999;434:3-10.
37. Baak JP, van Diest PJ, Ariens AT, et al. The multicenter morphometric mammary carcinoma project (MMMMCP). A nationwide prospective study on reproducibility and prognostic power of routine quantitative assessments in The Netherlands. Pathol Res Pract 1989;185:664-670.
38. Baak JP, van Diest PJ, Voorhorst FJ, et al. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph nodenegative breast cancer patients younger than 55 years. J Clin Oncol 2005;23:5993-6001.
39. de Jong JS, van Diest PJ, Baak JP. Hot spot microvessel density and the mitotic activity index are strong additional prognostic indicators in invasive breast cancer. Histopathology 2000;36:306-312.
40. Janicke F, Prechtl A, Thomssen C, et al. German N0 Study Group. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001;93:913-920.
41. Farmen RK, Nordgard O, Gilje B, et al. Bone marrow cytokeratin 19 mRNA level is an independent predictor of relapse-free survival in operable breast cancer patients. Breast Cancer Res Treat 2007; May 10 [E-pub ahead of print].